Xeris Pharmaceuticals Inc. (XERS) Misses Q2 EPS by 2c, beats revenue

Xeris Pharmaceuticals Inc. (NASDAQ: XERS) reported Q2 EPS of ($0.14), $0.02 worse than the analyst estimate of ($0.12). Revenue for the quarter came in at $38.01 million versus the consensus estimate of $35.23 million.

For earnings history and earnings-related data on Xeris Pharmaceuticals Inc. (XERS) click here.

You May Also Be Interested In

• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• Primoris cuts 2026 outlook on renewables cost overruns, COO exits
• Sun Communities names Ileana McAlary as general counsel and EVP